var data={"title":"Famciclovir: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Famciclovir: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is an oral prodrug that is converted by first-pass metabolism to the antiviral drug <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">Penciclovir</a>, upon intracellular uptake, is monophosphorylated by virally-encoded thymidine kinase and subsequently converted to a triphosphate by cellular enzymes. Penciclovir triphosphate preferentially inhibits the DNA polymerase of susceptible viruses; at clinically relevant levels, there is no substantial effect upon cellular DNA polymerase, thereby minimizing side effects to the host [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2\" class=\"abstract_t\">2</a>].</p><p>This mechanism is similar to that described for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>; however, compared with acyclovir triphosphate, <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> triphosphate has a lower affinity for viral DNA polymerase but a longer intracellular half-life [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Spectrum of activity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">Penciclovir</a> is active against herpes simplex virus (HSV) types 1 and 2, and varicella zoster virus (VZV). Epstein-Barr virus is also susceptible in vitro [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Mechanism of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanisms of resistance to <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> are similar to those described for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/3\" class=\"abstract_t\">3</a>]. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced or absent thymidine kinase</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered thymidine kinase activity resulting in decreased <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> phosphorylation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered viral DNA polymerase with decreased affinity for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> triphosphate</p><p/><p>(See <a href=\"topic.htm?path=acyclovir-an-overview#H4\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;, section on 'Mechanism of resistance'</a>.)</p><p>Most acyclovir-resistant strains of HSV and VZV exhibit cross-resistance to <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a>; reduced or absent viral thymidine kinase is the primary mechanism [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2,5\" class=\"abstract_t\">2,5</a>]. However, some acyclovir-resistant and foscarnet-resistant isolates remain susceptible to penciclovir. These strains demonstrate altered thymidine kinase and DNA polymerase substrate specificity [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2,5,6\" class=\"abstract_t\">2,5,6</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">BASIC PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is well absorbed, featuring an oral bioavailability of 77 percent [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/7\" class=\"abstract_t\">7</a>]. Prompt first-pass metabolism in the intestine and liver results in conversion to <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a>. A 500 mg dose of famciclovir yields peak penciclovir levels of 2.7 to 4 <span class=\"nowrap\">mg/L,</span> with a plasma half-life of 2.1 to 2.7 hours. Food has no clinically important effect upon these levels [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2\" class=\"abstract_t\">2</a>].</p><p>A key feature of <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in herpes simplex virus-infected cells, and 7 to 14 hours in varicella zoster virus-infected cells. In comparison, the intracellular half-life of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> triphosphate is one hour or less [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2\" class=\"abstract_t\">2</a>]. As a result, <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a> requires less frequent dosing.</p><p>Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/1,2\" class=\"abstract_t\">1,2</a>]. <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">Penciclovir</a> is removed by hemodialysis [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Well-compensated chronic liver disease does not require dose modification, but pharmacokinetic studies in patients with poorly compensated hepatic insufficiency have not been performed [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is very well tolerated, with a side effect profile similar to those of placebo and oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, although long-term safety data are unavailable [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>] (see <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a>). A review of over 1600 patients receiving famciclovir for herpes zoster or genital herpes revealed an adverse event profile not significantly different from placebo [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Use in pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> has been assigned to Pregnancy Category B; animal studies suggest safety, although there have been no adequate studies in pregnant women. In some cases, the potential benefits of therapy may outweigh the potential risks to the fetus. In order to monitor the outcomes of pregnancies exposed to this drug, SmithKline Beecham maintains a Famvir Pregnancy Registry at 800-366-8900, ext. 5231 [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">USE OF FAMCICLOVIR IN IMMUNOCOMPETENT PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is one possible treatment option for patients with acute herpes zoster [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/9,10\" class=\"abstract_t\">9,10</a>] and those with primary and recurrent genital herpes infection [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/11-13\" class=\"abstract_t\">11-13</a>]. The management and treatment of these infections is discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-herpes-zoster-in-the-immunocompetent-host\" class=\"medical medical_review\">&quot;Treatment of herpes zoster in the immunocompetent host&quot;</a> and <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">USE OF FAMCICLOVIR IN IMMUNOCOMPROMISED PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is one potential treatment option for herpes zoster and primary and recurrent genital herpes in immunocompromised patients [<a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/13-15\" class=\"abstract_t\">13-15</a>]. The approach to the treatment of genital herpes infections in the HIV-infected host is discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-genital-herpes-simplex-virus-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1414793\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is an oral prodrug which is converted by first-pass metabolism to the antiviral drug <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a>. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Upon intracellular uptake, <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> is mono-phosphorylated by virally-encoded thymidine kinase and subsequently converted to a triphosphate by cellular enzymes. Penciclovir triphosphate preferentially inhibits the DNA polymerase of susceptible viruses. At clinically relevant levels, there is no substantial effect upon cellular DNA polymerase, thereby minimizing side effects to the host. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">Penciclovir</a> is active against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). (See <a href=\"#H3\" class=\"local\">'Spectrum of activity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mechanisms of resistance to <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> are similar to those described for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. Most acyclovir-resistant strains of HSV and VZV exhibit cross-resistance to penciclovir. Resistance is rarely seen among immunocompetent hosts but has been well-documented in immunocompromised hosts, such as transplant recipients and HIV-infected patients. (See <a href=\"#H4\" class=\"local\">'Mechanism of resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A key feature of <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a> is a prolonged intracellular half-life of penciclovir triphosphate: 10 to 20 hours in HSV-infected cells, and 7 to 14 hours in VZV-infected cells. In comparison, the intracellular half-life of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> triphosphate is one hour or less. As a result, <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a> requires less frequent dosing. (See <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Excretion is primarily renal, and dose reduction is recommended in patients with impaired renal function (creatinine clearance under 60 <span class=\"nowrap\">mL/min)</span>. (See <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> is very well tolerated, with a side effect profile similar to that of placebo, although long-term safety data are unavailable. (See <a href=\"#H6\" class=\"local\">'Toxicity'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Famvir (famciclovir) prescribing information. SmithKline Beecham, 1997.</li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/2\" class=\"nounderline abstract_t\">Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50:396.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/3\" class=\"nounderline abstract_t\">Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/4\" class=\"nounderline abstract_t\">Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/5\" class=\"nounderline abstract_t\">Boyd MR, Safrin S, Kern ER. Penciclovir: A review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 1993; 4(Suppl 1):3.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/6\" class=\"nounderline abstract_t\">Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993; 37:2241.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/7\" class=\"nounderline abstract_t\">Vere Hodge RA. Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993; 4:67.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/8\" class=\"nounderline abstract_t\">Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994; 38:2454.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/9\" class=\"nounderline abstract_t\">Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/10\" class=\"nounderline abstract_t\">Boon RJ, Griffin DR. Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Neurology 1995; 45:S76.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/11\" class=\"nounderline abstract_t\">Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first-episode genital herpes. IDCP 1997; 6:S12.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/12\" class=\"nounderline abstract_t\">Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996; 276:44.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/13\" class=\"nounderline abstract_t\">Sacks SL. Management of recurrent genital herpes &mdash; episodic therapy with famciclovir. IDCP 1997; 6:S5.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/14\" class=\"nounderline abstract_t\">Frechette G, Romanowski B. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. Can J Infect Dis 1997; 8:44A.</a></li><li><a href=\"https://www.uptodate.com/contents/famciclovir-an-overview/abstract/15\" class=\"nounderline abstract_t\">Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8338 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1414793\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Spectrum of activity</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Mechanism of resistance</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">BASIC PHARMACOKINETICS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">TOXICITY</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Use in pregnancy</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">USE OF FAMCICLOVIR IN IMMUNOCOMPETENT PATIENTS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">USE OF FAMCICLOVIR IN IMMUNOCOMPROMISED PATIENTS</a></li><li><a href=\"#H1414793\" id=\"outline-link-H1414793\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">Acyclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-genital-herpes-simplex-virus-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Treatment of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-herpes-zoster-in-the-immunocompetent-host\" class=\"medical medical_review\">Treatment of herpes zoster in the immunocompetent host</a></li></ul></div></div>","javascript":null}